Pfizer's sales of its RSV vaccine, Abrysvo, declined in the third quarter compared to the same period last year. However, the company remains optimistic about its market potential and has seen an increase in market share.
The total revenue from Abrysvo for the first nine months of the year has significantly risen due to the timing of the vaccine's approval for older adults in the U.S. Pfizer's market share has surpassed 50% of the shipped volume for the third quarter, despite competition from GSK.
The Centers for Disease Control and Prevention (CDC) has updated its guidance on RSV vaccinations, leading to a decrease in vaccination volumes among older adults. However, there has been a surge in maternal vaccinations, which is seen as a promising avenue for growth.
Pfizer is also developing next-generation pneumococcal vaccines to replace its top-selling Prevnar 20, but faces competition in this market. Analysts have expressed concerns about Pfizer's ability to compete effectively.
In summary, Pfizer is strategically positioning itself to capture a larger market share and expand its product offerings, but faces challenges in the evolving regulatory landscape and competitive pressures.